Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy
Peter Kletting
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Author to whom correspondence should be addressed. Electronic mail: [email protected]; Telephone: ++49 731 500 61371; Fax: ++49 731 500 61302.
Search for more papers by this authorBerthold Müller
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorBahar Erentok
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Search for more papers by this authorJörn Schmaljohann
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorFlorian F. Behrendt
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorSven N. Reske
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Search for more papers by this authorFelix M. Mottaghy
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany and Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht 6229, The Netherlands
Search for more papers by this authorGerhard Glatting
Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim 68167, Germany
Search for more papers by this authorPeter Kletting
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Author to whom correspondence should be addressed. Electronic mail: [email protected]; Telephone: ++49 731 500 61371; Fax: ++49 731 500 61302.
Search for more papers by this authorBerthold Müller
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorBahar Erentok
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Search for more papers by this authorJörn Schmaljohann
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorFlorian F. Behrendt
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany
Search for more papers by this authorSven N. Reske
Klinik für Nuklearmedizin, Universität Ulm, Ulm 89081, Germany
Search for more papers by this authorFelix M. Mottaghy
Klinik für Nuklearmedizin, Aachen University, RWTH, Aachen 52074, Germany and Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht 6229, The Netherlands
Search for more papers by this authorGerhard Glatting
Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim 68167, Germany
Search for more papers by this authorAbstract
Purpose:
An important assumption in dosimetry prior to radionuclide therapy is the equivalence of pretherapeutic and therapeutic biodistribution. In this study the authors investigate if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used.
Methods:
Physiologically based pharmacokinetic models were developed. Gamma camera and serum measurements of ten patients with metastasizing neuroendocrine tumors were conducted using111In-DTPAOC. The most suitable model was selected using the corrected Akaike information criterion. Based on that model and the estimated individual parameters, predicted and measured 90Y-DOTATATE excretions during therapy were compared. The residence times for the pretherapeutic (measured) and therapeutic scenarios (simulated) were calculated.
Results:
Predicted and measured therapeutic excretion differed in three patients by 10%, 31%, and 7%. The measured pretherapeutic and therapeutic excretion differed by 53%, 56%, and 52%. The simulated therapeutic residence times of kidney and tumor were 3.1 ± 0.6 and 2.5 ± 1.2 fold higher than the measured pretherapeutic ones.
Conclusions:
To avoid the introduction of unnecessary inaccuracy in dosimetry, using the same substance along with the same amount for pretherapeutic measurements and therapy is recommended.
Supporting Information
| Filename | Description |
|---|---|
| mp7266-sup-0001.tiffapplication/tiff, 2.8 MB | Supplementary Material |
| mp7266-sup-0002.docapplication/doc, 214 KB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1S. E. Pool, E. P. Krenning, G. A. Koning, C. H. van Eijck, J. J. Teunissen, B. Kam, R. Valkema, D. J. Kwekkeboom, and M. de Jong, “Preclinical and clinical studies of peptide receptor radionuclide therapy,” Semin. Nucl. Med. 40, 209–218 (2010). 10.1053/j.semnuclmed.2009.12.001
- 2M. Cremonesi, M. Ferrari, A. Di Dia, F. Botta, C. De Cicco, L. Bodei, and G. Paganelli, “Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy,” Q. J. Nucl. Med. Mol. Imaging 55, 155–167 (2011).
- 3E. Vegt, M. de Jong, J. F. M. Wetzels, R. Masereeuw, M. Melis, W. J. G. Oyen, M. Gotthardt, and O. C. Boerman, “Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention,” J. Nucl. Med. 51, 1049–1058 (2010). 10.2967/jnumed.110.075101
- 4E. J. Rolleman, M. Melis, R. Valkema, O. C. Boerman, E. P. Krenning, and M. de Jong, “Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues,” Eur. J. Nucl. Med. Mol. Imaging 37, 1018–1031 (2010). 10.1007/s00259-009-1282-y
- 5M. Konijnenberg, “From imaging to dosimetry and biological effects,” Q. J. Nucl. Med. Mol. Imaging 55, 44–56 (2011).
- 6P. Kletting, D. Bunjes, M. Luster, S. N. Reske, and G. Glatting, “Optimal preloading in radioimmunotherapy with anti-CD45 antibody,” Med. Phys. 38, 2572–2578 (2011). 10.1118/1.3581059
- 7P. Kletting, T. Kull, D. Bunjes, B. Mahren, M. Luster, S. N. Reske, and G. Glatting, “Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model,” J. Nucl. Med. 51, 484–491 (2010). 10.2967/jnumed.109.067546
- 8M. de Jong, W. A. Breeman, B. F. Bernard, A. van Gameren, E. de Bruin, W. H. Bakker, M. E. van der Pluijm, T. J. Visser, H. R. Macke, and E. P. Krenning, “Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount,” Eur. J. Nucl. Med. 26, 693–698 (1999). 10.1007/s002590050439
- 9M. Melis, R. Valkema, E. P. Krenning, and M. de Jong, “Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration,” J. Nucl. Med. 53, 749–753 (2012). 10.2967/jnumed.111.098665
- 10D. J. Kwekkeboom, B. L. Kam, M. van Essen, J. J. Teunissen, C. H. van Eijck, R. Valkema, M. de Jong, W. W. de Herder, and E. P. Krenning, “Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors,” Endocr. Relat. Cancer 17, R53–73 (2010). 10.1677/ERC-09-0078
- 11J. B. Cwikla, A. Sankowski, N. Seklecka, J. R. Buscombe, A. Nasierowska-Guttmejer, K. G. Jeziorski, R. Mikolajczak, D. Pawlak, K. Stepien, and J. Walecki, “Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study,” Ann. Oncol. 21, 787–794 (2010). 10.1093/annonc/mdp372
- 12J. P. Esser, E. P. Krenning, J. J. M. Teunissen, P. P. M. Kooij, A. L. H. van Gameren, W. H. Bakker, and D. J. Kwekkeboom, “Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0, Tyr3]octreotide: Which peptide is preferable for PRRT?,” Eur. J. Nucl. Med. Mol. Imaging 33, 1346–1351 (2006). 10.1007/s00259-006-0172-9
- 13F. Y. Bois, “Physiologically based modelling and prediction of drug interactions,” Basic Clin. Pharmacol. Toxicol. 106, 154–161 (2010). 10.1111/j.1742-7843.2009.00488.x
- 14E. L. Bradshaw-Pierce, S. G. Eckhardt, and D. L. Gustafson, “A physiologically based pharmacokinetic model of docetaxel disposition: From mouse to man,” Clin. Cancer Res. 13, 2768–2776 (2007). 10.1158/1078-0432.CCR-06-2362
- 15P. Kletting, T. Kull, S. N. Reske, and G. Glatting, “Comparing time activity curves using the Akaike information criterion,” Phys. Med. Biol. 54, N501–N507 (2009). 10.1088/0031-9155/54/21/N01
- 16K. P. Burnham and D. R. Anderson, Model Selection and Multimodel Interference-A practical Information-Theoretic Approach, 2nd ed. (Springer, New York, 2002).
- 17L. Geworski, A. Schaefer, B. O. Knoop, J. Pinkert, M. Plotkin, and C. M. Kirsch, “Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy,” Nuklearmedizin 49, 85–95 (2010). 10.3413/nukmed-0283
- 18G. Glatting, M. Landmann, T. Kull, A. Wunderlich, N. M. Blumstein, A. K. Buck, and S. N. Reske, “Internal radionuclide therapy: The UlmDos software for treatment planning,” Med. Phys. 32, 2399–2405 (2005). 10.1118/1.1945348
- 19M. de Jong, W. H. Bakker, E. P. Krenning, W. A. Breeman, M. E. van der Pluijm, B. F. Bernard, T. J. Visser, E. Jermann, M. Behe, P. Powell, and H. R. Macke, “90Yttrium and 111Indium labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy,” Eur. J. Nucl. Med. 24, 368–371 (1997). 10.1007/s002590050064
- 20C. Boy, T. A. Heusner, T. D. Poeppel, A. Redmann-Bischofs, N. Unger, W. Jentzen, W. Brandau, K. Mann, G. Antoch, A. Bockisch, and S. Petersenn, “68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: Correlation of sst2 mRNA and SUV(max),” Eur. J. Nucl. Med. Mol. Imaging 38, 1224–1236 (2011). 10.1007/s00259-011-1760-x
- 21B. Rippe and B. Haraldsson, “Transport of macromolecules across microvascular walls: The two-pore theory,” Physiol. Rev. 74, 163–219 (1994). 10.2466/pr0.1994.74.1.163
- 22A. Guyennon, M. Mihaila, J. Palma, C. Lombard-Bohas, J. A. Chayvialle, and F. Pilleul, “Perfusion characterization of liver metastases from endocrine tumors: Computed tomography perfusion,” World J. Radiol. 2, 449–454 (2010). 10.4329/wjr.v2.i11.449
- 23R. W. Leggett and L. R. Williams, “A proposed blood circulation model for reference man,” Health Phys. 69, 187–201 (1995). 10.1097/00004032-199508000-00003
- 24G. D. Thomas, M. J. Chappell, P. W. Dykes, D. B. Ramsden, K. R. Godfrey, J. R. Ellis, and A. R. Bradwell, “Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: A biomathematical model,” Cancer Res. 49, 3290–3296 (1989).
- 25J. C. Reubi, J. C. Schar, B. Waser, S. Wenger, A. Heppeler, J. S. Schmitt, and H. R. Macke, “Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” Eur. J. Nucl. Med. 27, 273–282 (2000). 10.1007/s002590050034
- 26W. B. Edwards, C. G. Fields, C. J. Anderson, T. S. Pajeau, M. J. Welch, and G. B. Fields, “Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs,” J. Med. Chem. 37, 3749–3757 (1994). 10.1021/jm00048a011
- 27G. Z. Ferl, R. A. Dumont, I. J. Hildebrandt, A. Armijo, R. Haubner, G. Reischl, H. Su, W. A. Weber, and S.-C. Huang, “Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice,” J. Nucl. Med. 50, 250–258 (2009). 10.2967/jnumed.108.054049
- 28L. J. Hofland and S. W. Lamberts, “The pathophysiological consequences of somatostatin receptor internalization and resistance,” Endocr. Rev. 24(1), 28–47 (2003). 10.1210/er.2000-0001
- 29B. Waser, M. L. Tamma, R. Cescato, H. R. Maecke, and J. C. Reubi, “Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues,” J. Nucl. Med. 50, 936–941 (2009). 10.2967/jnumed.108.061457
- 30E. P. Krenning, W. H. Bakker, P. P. M. Kooij, W. A. P. Breeman, H. Y. Oei, M. de Jong, J. C. Reubi, T. J. Visser, C. Bruns, D. J. Kwekkeboom, A. E. M. Reijs, P. M. van Hagen, J. W. Koper, and S. W. J. Lamberts, “Somatostatin receptor scintigraphy with indium-111-DTPA-D-PHe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-tyr-3-octreotide,” J. Nucl. Med. 33, 652–658 (1992).
- 31M. M. Schmidt and K. D. Wittrup, “A modeling analysis of the effects of molecular size and binding affinity on tumor targeting,” Mol. Cancer Ther. 8, 2861–2871 (2009). 10.1158/1535-7163.MCT-09-0195
- 32P. Kletting, D. Bunjes, S. N. Reske, and G. Glatting, “Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model,” J. Nucl. Med. 50, 296–302 (2009). 10.2967/jnumed.108.054189
- 33P. H. Barrett, B. M. Bell, C. Cobelli, H. Golde, A. Schumitzky, P. Vicini, and D. M. Foster, “SAAM II: Simulation, analysis, and modeling software for tracer and pharmacokinetic studies,” Metabolism 47, 484–492 (1998). 10.1016/S0026-0495(98)90064-6
- 34G. Glatting, P. Kletting, S. N. Reske, K. Hohl, and C. Ring, “Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test,” Med. Phys. 34, 4285–4292 (2007). 10.1118/1.2794176
- 35P. Kletting, S. N. Reske, and G. Glatting, “Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: A simulation study,” Z. Med. Phys. 21, 301–304 (2011). 10.1016/j.zemedi.2011.03.003
- 36I. Velikyan, A. Sundin, B. Eriksson, H. Lundqvist, J. Sorensen, M. Bergstrom, and B. Langstrom, “In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours–Impact of peptide mass,” Nucl. Med. Biol. 37, 265–275 (2010). 10.1016/j.nucmedbio.2009.11.008
- 37J. M. Beauregard, M. S. Hofman, G. Kong, and R. J. Hicks, “The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: Implications for peptide receptor radionuclide therapy,” Eur. J. Nucl. Med. Mol. Imaging 39, 50–56 (2012). 10.1007/s00259-011-1937-3
- 38D. J. Kwekkeboom, W. H. Bakker, P. P. Kooij, M. W. Konijnenberg, A. Srinivasan, J. L. Erion, M. A. Schmidt, J. L. Bugaj, M. de-Jong, and E. P. Krenning, “[177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients,” Eur. J. Nucl. Med. 28, 1319–1325 (2001). 10.1007/s002590100574
- 39G. J. Förster, M. J. Engelbach, J. J. Brockmann, H. J. Reber, H. G. Buchholz, H. R. Mäcke, F. R. Rösch, H. R. Herzog, and P. R. Bartenstein, “Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: Comparison of 86Y-DOTATOC and 111In-DTPA-octreotide,” Eur. J. Nucl. Med. 28, 1743–1750 (2001). 10.1007/s002590100628
- 40See supplementary material at http://dx.doi.org/10.1118/1.4747266 E-MPHYA6-39-043209 for the following: Supplement 1 contains all fits of patient 1-10 using model A2 and Supplement 2 contains all equations and parameter descriptions.
10.1118/1.4747266 Google Scholar
